A promising gene therapy trial, derailed by cancerous side effects in a young patient, is set to reboot with the help of next generation gene-transfer vectors.
A biologist and a physicist collaborate on a decade-long exploration of the physical parameters of membrane traffic in eukaryotic cells.
In discovering their shared ancestry, a distantly related animal geneticist and plant pathologist find a common thread in their work on immune receptors.
Drugs that target specific tumors are harbingers of a new era of genetically informed medicine.
Institut Curie researchers Bruno Goud, a biologist, and Patricia Bassereau, a physicist, talk about their fruitful, decade-long collaboration exploring the physics of membrane trafficking in a Skype interview conducted by Associate Editor Richard P. Grant.
Recent clinical trials have reignited the interest in simple anti-inflammatory drugs like aspirin for controlling the inflammation associated with cancer.
Can tumors—which can originate from, and often resemble, chronically inflamed tissue—be curtailed using familiar anti-inflammatory agents, without their side effects?
Preston Estep discusses the role that telomeres play in the aging process.
A snapshot of the highest-ranked articles from a 30-day period on Faculty of 1000
Epigenetic marks laid down during the cold months of the year allow flowering in spring and summer.
After implantation, the tissue developed blood vessels and became integrated into neuronal networks in the animals’ brains.
The nationwide experiment will initially include around 100,000 volunteers.
The 20-year project calls into question the conventional wisdom about the role plants will play in mitigating future climate change.
The US Senate narrowly approved the politician, who does not have a science background.
© 1986-2018 The Scientist
